Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants

NCT04075409 is registered in ClinicalTrials.gov with UCB Biopharma S.P.R.L. as lead sponsor.

NCT NCT04075409
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04075409 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Parallel Group, Single-Center Study to Investigate the Pharmacokinetic, Safety, and Tolerability Profiles of Padsevonil in CYP2C19 Genotyped Healthy Male Japanese Study Participants
Lead sponsor
UCB Biopharma S.P.R.L.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2019
Completion date
December 27, 2019
Enrollment
39 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy japanese participants